| Literature DB >> 30275568 |
Marco Ruella1,2,3,4,5, Jun Xu1,2,3, David M Barrett6, Joseph A Fraietta1,2,3,4, Tyler J Reich1, David E Ambrose1, Michael Klichinsky1,7, Olga Shestova1, Prachi R Patel1, Irina Kulikovskaya1, Farzana Nazimuddin1, Vijay G Bhoj1,2,3, Elena J Orlando8, Terry J Fry9, Hans Bitter8, Shannon L Maude6, Bruce L Levine1,2,3, Christopher L Nobles10, Frederic D Bushman10, Regina M Young1, John Scholler1, Saar I Gill1,3,5, Carl H June11,12,13,14, Stephan A Grupp6, Simon F Lacey1,2,3, J Joseph Melenhorst15,16,17.
Abstract
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19- leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30275568 PMCID： PMC6511988 DOI： 10.1038/s41591-018-0201-9
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440